Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Effect of HLA class I expression on the tumor immune microenvironment and prognosis in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Risk factors like Gleason score, cancer stage, PSA levels, and genetic markers guide prostate cancer treatment decisions. Treatment options include active surveillance, surgery, radiation, hormone ...

An article about the importance of PSA testing for early detection and treatment of prostate cancer ...

IN the fight against prostate cancer, one biomarker is proving to be a game changer. According to Sunway Medical Centre Clinical Head and Nuclear Medicine Physician Associate Professor Dr Tan Teik Hin ...

According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...